DFTX
Definium Therapeutics Inc.

25,839
Mkt Cap
$1.8B
Volume
704.00
52W High
$19.62
52W Low
$4.70
PE Ratio
-8.73
DFTX Fundamentals
Price
$18.32
Prev Close
$18.06
Open
$18.30
50D MA
$16.60
Beta
1.80
Avg. Volume
1.38M
EPS (Annual)
-$2.06
P/B
5.37
Rev/Employee
$0.00
$825.08
Loading...
Loading...
News
all
press releases
Boxer Capital Management LLC Takes Position in Definium Therapeutics, Inc. $DFTX
Boxer Capital Management LLC purchased a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference
Definium Therapeutics (NASDAQ:DFTX) outlined its clinical pipeline and upcoming data catalysts at the Leerink Partners Global Healthcare Conference, with CEO Robert Barrow and CFO Brandi Roberts...
MarketBeat·2d ago
News Placeholder
Commodore Capital LP Lowers Holdings in Definium Therapeutics, Inc. $DFTX
Commodore Capital LP lowered its stake in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) by 35.5% during the 3rd quarter, according to the company in its most recent Form 13F...
MarketBeat·2d ago
News Placeholder
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX
Ally Bridge Group NY LLC trimmed its holdings in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) by 50.2% in the 3rd quarter, according to its most recent disclosure with the SEC...
MarketBeat·2d ago
News Placeholder
Rosalind Advisors Inc. Has $8.84 Million Holdings in Definium Therapeutics, Inc. $DFTX
Rosalind Advisors Inc. increased its holdings in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) by 78.6% during the third quarter, according to the company in its most recent Form...
MarketBeat·4d ago
News Placeholder
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of "Buy" by Analysts
Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) have been given an average recommendation of "Buy" by the twelve ratings firms that are presently covering the firm...
MarketBeat·6d ago
News Placeholder
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year High - Here's Why
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year High - Time to Buy...
MarketBeat·7d ago
News Placeholder
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics, Inc. (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric...
Business Wire·8d ago
News Placeholder
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...
PR Newswire·8d ago
News Placeholder
Royce & Associates LP Invests $955,000 in Definium Therapeutics, Inc. $DFTX
Royce & Associates LP purchased a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·10d ago
<
1
2
...
>

Latest DFTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.